Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M BEAR

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1689643645
CMS profile
211881
Location
PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$139,461.82

324 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 6 of 7; records 251–300 of 324 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M BEAR

NPI 1689643645 · CMS profile ID 211881

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 324 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689643645?year=2025&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M BEAR, NPI 1689643645, CMS profile ID 211881. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 324 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689643645?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID M BEAR, NPI 1689643645, CMS profile ID 211881. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 324 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689643645?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID M BEAR, NPI 1689643645, CMS profile ID 211881, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 324 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1689643645?year=2025&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

324 matching records · $139,461.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 324 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 324.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $9.6603/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488075 CMS
PFIZER INC. $6.7203/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231498039 CMS
PFIZER INC. $17.0803/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231501998 CMS
EMD Serono, Inc. $22.2703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236918830 CMS
ABBVIE INC. $15.4203/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488071 CMS
ABBVIE INC. $6.9803/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488073 CMS
ABBVIE INC. $2.0303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488069 CMS
JAZZ PHARMACEUTICALS INC. $27.0203/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234326385 CMS
JAZZ PHARMACEUTICALS INC. $0.7003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234349294 CMS
Teva Pharmaceuticals USA, Inc. $51.5003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247277721 CMS
Averitas Pharma Inc. $19.6803/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248544881 CMS
PFIZER INC. $2.5503/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231475177 CMS
ABBVIE INC. $6.3603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488067 CMS
JAZZ PHARMACEUTICALS INC. $19.9403/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234336913 CMS
PFIZER INC. $6.8403/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231481264 CMS
Genentech USA, Inc. $24.4303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211507264 CMS
Axsome Therapeutics, Inc. $26.9303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235481306 CMS
ABBVIE INC. $26.0503/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488065 CMS
Amgen Inc. $19.0203/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228384168 CMS
Lilly USA, LLC $106.4003/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186570844 CMS
Lundbeck LLC $12.3603/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251771050 CMS
REVANCE THERAPEUTICS, INC. $22.5703/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251158785 CMS
Lilly USA, LLC $79.1003/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186590976 CMS
Novartis Pharmaceuticals Corporation $14.4503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005634 CMS
Novartis Pharmaceuticals Corporation $0.5503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005636 CMS
PFIZER INC. $7.4103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231648956 CMS
AstraZeneca Pharmaceuticals LP $19.4003/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206893308 CMS
Octapharma USA, Inc. $29.6302/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245075317 CMS
PFIZER INC. $6.7202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231648097 CMS
ABBVIE INC. $22.6802/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488061 CMS
ABBVIE INC. $2,625.0002/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201488063 CMS
SK Life Science, Inc. $28.6002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252279609 CMS
ABBVIE INC. $10.2602/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488059 CMS
ACADIA Pharmaceuticals Inc $16.5802/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247766543 CMS
Eisai Inc. $22.2202/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244475481 CMS
PFIZER INC. $2.1002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231545117 CMS
Alexion Pharmaceuticals, Inc. $18.4402/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202949104 CMS
Celgene Corporation $17.3202/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184584641 CMS
Lilly USA, LLC $1,450.0002/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186605760 CMS
Lilly USA, LLC $2,300.0002/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186628237 CMS
Lilly USA, LLC $2,300.0002/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186641571 CMS
Otsuka America Pharmaceutical, Inc. $19.4902/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227292769 CMS
JAZZ PHARMACEUTICALS INC. $71.9002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234311673 CMS
Novartis Pharmaceuticals Corporation $20.7302/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005630 CMS
PFIZER INC. $15.1702/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231362150 CMS
Lilly USA, LLC $5.7702/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186570842 CMS
Lilly USA, LLC $155.6802/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186616282 CMS
ABBVIE INC. $9.6602/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488057 CMS
ABBVIE INC. $95.9902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201488055 CMS
Tanabe Pharma America, Inc. $15.7802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243918663 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,672.87 277
PY2020 $70,847.13 318
PY2021 $59,031.55 275
PY2022 $67,086.92 293
PY2023 $37,886.67 297
PY2024 $95,809.13 332
PY2025 $139,461.82 324

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $27,100.00 8
PY2025 Principal investigator $1,784,588.49 21
PY2024 Recipient $71,256.43 5
PY2024 Principal investigator $2,611,551.51 15
PY2023 Recipient $13,837.50 3
PY2023 Principal investigator $2,487,668.88 17
PY2022 Recipient $32,185.00 4
PY2022 Principal investigator $1,653,045.59 11
PY2021 Recipient $10,622.83 8
PY2021 Principal investigator $846,711.49 21
PY2020 Recipient $26,338.95 4
PY2020 Principal investigator $132,181.16 5
PY2019 Principal investigator $38,255.67 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Ipsen Innovation $500.00 12/24/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291324
Recipient Ipsen Innovation $2,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291312
Recipient Ipsen Innovation $3,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291314
Recipient Ipsen Innovation $1,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291316
Recipient Ipsen Innovation $12,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291318
Recipient Ipsen Innovation $1,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291320
Recipient Ipsen Innovation $1,100.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291322
Recipient Ipsen Innovation $5,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291326
Principal investigator 1 Novartis Pharmaceuticals Corporation $50.00 12/01/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304137
Principal investigator 1 Ipsen Innovation $126.00 10/03/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288540
Principal investigator 1 Ipsen Innovation $695.00 09/26/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288536
Principal investigator 1 Ipsen Innovation $2,790.00 09/26/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288538
Principal investigator 1 Eli Lilly and Company $2,439.00 07/10/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187880583
Principal investigator 1 Eli Lilly and Company $22,283.00 06/23/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187880207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $47,604.75 02/19/2025 Non-covered Recipient Entity
Synergy Clinical Research Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235993385
Principal investigator 1 Novartis Pharmaceuticals Corporation $411,632.44 02/19/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190311825
Principal investigator 1 Eli Lilly and Company $52.05 02/12/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883992
Principal investigator 1 Eli Lilly and Company $108,960.00 01/28/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187879919
Principal investigator 1 Eli Lilly and Company $536,774.00 01/28/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187880581
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,930.00 01/28/2025 Non-covered Recipient Entity
SYNERGY CLINICAL RESEARCH LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305593
Principal investigator 1 Eli Lilly and Company $786.83 01/27/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187880799
Principal investigator 1 Eli Lilly and Company $2,396.14 01/27/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883536
Principal investigator 1 Eli Lilly and Company $117,410.00 01/17/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187883328
Principal investigator 1 Eli Lilly and Company $18,291.38 01/09/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881234
Principal investigator 1 Eli Lilly and Company $265,252.00 01/07/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881712
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,827.25 01/07/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190313245
Principal investigator 1 Eli Lilly and Company $8,476.57 01/06/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187881804
Principal investigator 1 Sage Therapeutics, LLC $18,025.00 01/06/2025 Non-covered Recipient Entity
SYNERGY CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1206580288
Principal investigator 1 Novartis Pharmaceuticals Corporation $155,787.08 01/01/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304139